Incidence of Thrombotic Events with CDK4/6 Inhibitor Use in Real-World Practice Compared with Clinical Trial Settings
Thrombotic event incidence was higher in this real-world study than that which was reported in clinical trials, with arterial thrombosis accounting for more than one-third of events.
Assessment of Characteristics, Utilization Patterns, and Outcomes in the Real-World Setting of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with Abemaciclib
Results of this real-world study demonstrated that the impact of abemaciclib complements the pivotal clinical trial data.
Capecitabine or Endocrine Therapy as Maintenance Therapy for Hormone Receptor–Positive, HER2-Negative Breast Cancer
Primary analysis of a multicenter, randomized clinical trial suggests that endocrine therapy demonstrates benefits over capecitabine when used as a maintenance therapy after first-line combination chemotherapy in hormone receptor–positive, HER2-negative advanced metastatic breast cancer.
Real-World Data of Palbociclib and Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
This real-world study of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with a palbociclib-based therapy as either first- or second-line therapy, showed similar safety and efficacy when compared with clinical study results.
Impact of the COVID-19 Pandemic in the United States on First-Line Treatment Trends in Metastatic Breast Cancer
During the COVID-19 pandemic, there was a decline in the number of patients beginning first-line treatment. There was a decrease in the percentage of patients receiving CDK4/6 inhibitor combination therapy while a simultaneous increase in endocrine monotherapy was observed.
Updated Results from the Phase 3b CompLEEment-1 Study of Ribociclib plus Letrozole in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a large, diverse cohort of patients, this analysis confirms the safety and efficacy of ribociclib plus letrozole with data that are consistent with those observed in the MONALEESA trials, supporting the use of this combination in the first-line setting.
For Patients with PIK3CA Mutation–Positive Advanced Breast Cancer, Treatment with Alpelisib plus Fulvestrant May Be Beneficial
When combined with fulvestrant, alpelisib produced clinically and statistically relevant progression-free survival despite the baseline poorer prognosis in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer.
Perspectives on Balancing Toxicity and Efficacy When Managing Advanced HER2-Negative Breast Cancer with First-Line Treatment
Patients and oncologists are prepared to make trade-offs between efficacy and toxicities, but patients appreciate toxicities impacting quality of life while endeavoring to increase survival.
Efficacy Study of Everolimus and Exemestane for the Treatment of Patients with Metastatic Hormone Receptor–Positive Breast Cancer Previously Treated with CDK4/6 Inhibitors
In patients with metastatic hormone receptor–positive breast cancer treated previously with a CDK4/6 inhibitor, there was a lower median progression-free survival benefit from everolimus in combination with exemestane compared with those patients who had not received this combination.
Effect of Concomitant Treatment with Radiation Therapy and CDK4/6 in Patients with Advanced Breast Cancer
In this study, a high rate of radiation toxicity was observed in patients with advanced breast cancer treated with CDK4/6 inhibitors.